EGFR and non-small cell lung carcinoma: Here we displayed that ASP4132 treatment similarly induced PDGFRα-EGFR protein degradation and inhibited downstream Akt activation in NSCLC cells and xenograft tumor tissues (Figs. 4 and 6).